Aldeyra Therapeutics (FRA:137) Cyclically Adjusted FCF per Share: €-1.07 (As of Mar. 2026)


FRA:137 Aldeyra Therapeutics Inc FRA:137
29 GF Score
Price €1.84
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics Cyclically Adjusted FCF per Share?

Aldeyra Therapeutics FRA:137 -8.00% 29 Cyclically Adjusted FCF per Share is €-1.07 as of Mar. 2026. GuruFocus rates FRA:137 with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aldeyra Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.073. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.07 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Aldeyra Therapeutics was 6.80% per year. The lowest was 6.80% per year. And the median was 6.80% per year.

As of today (2026-07-11), Aldeyra Therapeutics's current stock price is €1.84. Aldeyra Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-1.07. Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Aldeyra Therapeutics  (FRA:137) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aldeyra Therapeutics Cyclically Adjusted FCF per Share Related Terms


Aldeyra Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics Cyclically Adjusted FCF per Share Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.48 -1.23 -1.28 -1.06

Aldeyra Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.40 -1.11 -1.10 -1.06 -1.07

FRA:137 vs ONCY, VRCA, CUE: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:137
29GF Score
Aldeyra Therapeutics Inc FRA:137
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aldeyra Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.073/330.2130*330.2130
=-0.073

Current CPI (Mar. 2026) = 330.2130.

Aldeyra Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.273 241.018 -0.374
201609 -0.250 241.428 -0.342
201612 -0.295 241.432 -0.403
201703 -0.285 243.801 -0.386
201706 -0.312 244.955 -0.421
201709 -0.253 246.819 -0.338
201712 -0.221 246.524 -0.296
201803 -0.339 249.554 -0.449
201806 -0.273 251.989 -0.358
201809 -0.316 252.439 -0.413
201812 -0.267 251.233 -0.351
201903 -0.413 254.202 -0.536
201906 -0.420 256.143 -0.541
201909 -0.278 256.759 -0.358
201912 -0.365 256.974 -0.469
202003 -0.476 258.115 -0.609
202006 -0.223 257.797 -0.286
202009 -0.140 260.280 -0.178
202012 -0.177 260.474 -0.224
202103 -0.248 264.877 -0.309
202106 -0.139 271.696 -0.169
202109 -0.124 274.310 -0.149
202112 -0.176 278.802 -0.208
202203 -0.201 287.504 -0.231
202206 -0.324 296.311 -0.361
202209 -0.217 296.808 -0.241
202212 -0.181 296.797 -0.201
202303 -0.150 301.836 -0.164
202306 -0.210 305.109 -0.227
202309 -0.127 307.789 -0.136
202312 0.008 306.746 0.009
202403 -0.154 312.332 -0.163
202406 -0.207 314.175 -0.218
202409 -0.121 315.301 -0.127
202412 -0.193 315.605 -0.202
202503 -0.193 319.799 -0.199
202506 -0.124 322.561 -0.127
202509 -0.099 324.800 -0.101
202512 -0.075 324.054 -0.076
202603 -0.073 330.213 -0.073

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.07 mean?
Aldeyra Therapeutics (FRA:137) has a Cyclically Adjusted FCF per Share of €-1.07 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aldeyra Therapeutics and its competitors.
Is Aldeyra Therapeutics' Cyclically Adjusted FCF per Share too high?
Aldeyra Therapeutics' current Cyclically Adjusted FCF per Share is €-1.07. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' Cyclically Adjusted FCF per Share compare to ONCY and VRCA?
Aldeyra Therapeutics' Cyclically Adjusted FCF per Share of €-1.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aldeyra Therapeutics and its competitors. Aldeyra Therapeutics's current Cyclically Adjusted FCF per Share is €-1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (FRA:137) has a current Cyclically Adjusted FCF per Share of €-1.07. The current Cyclically Adjusted FCF per Share is €-1.07. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Aldeyra Therapeutics (FRA:137), the current Cyclically Adjusted FCF per Share is €-1.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Other Exchanges ALDX:USA137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for FRA:137

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.84
Price